Posts Tagged ‘Implantable’

Allergan Sees MIGS as “Ready to Explode”

Allergan purchased AqueSys (developer of the Xen Gel Stent) in a $20 million deal earlier this year. “Just a few years ago, the energy and excitement in ophthalmology was not in glaucoma,” said Dave LeCause, vice president, US eye care. Between 2010 and 2014, the US glaucoma market remained flat, but the introduction of micro-invasive…

Read More

Refocus VIS Requires No Compromise

Refocus Group’s goal, according to CEO Mike Judy, is to become the preferred surgical alternative for the treatment of presbyopia. The VisAbility Implant System (VIS) is a “simplified procedure that delivers secure, uncomplicated, and consistent placement of the scleral implants,” he said. “This platform offers the only presbyopic solution that provides a full range of…

Read More

What’s New with Three Sustained-Release Drug Platforms

What’s New With Three Sustained-Release Drug Platforms - Eye on Innovation

Most ophthalmic drugs are delivered by topical application or direct injection into the vitreous, and many are limited by difficulties in sustaining therapeutic drug levels or by problems with patient adherence. As effective as topical drops are for delivering medication to the eye, they are wholly dependent on patient adherence. Even patients with potentially blinding…

Read More

Alcon Makes Big Move in MIGS

Alcon Makes Big

With Transcend, Alcon Gains a Foothold in Glaucoma Device Market Contributed by Larry Haimovitch and Richard Mark Kirkner With its move to acquire Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery (MIGS) device market…

Read More

MicroOptx Pursues New MIGS Approach

MicroOptx Pursues New MIGS Approach

Chris Pulling, CEO of MicroOptx, tells OISTV about its Brown Glaucoma Implant (new name pending). The implant is used to lower IOP by draining aqueous fluid. Unlike other implants, which divert fluid to other chambers of the eye, MicroOptx is shunts the fluid to the tear film. Speaking With: Chris Pulling Chris was most recently…

Read More

Second Sight Medical Products

Second Sight Medical Products

The Argus II transmits images wirelessly to a layer of 60 tiny electrodes on the retina inside the eye, to reverse vision lost as a result of retinitis pigmentosa (RP). The product is commercial stage, approved in the United States, Canada, European Union, Turkey, and elsewhere. RP is a hereditary disease; the Argus II is…

Read More

Alimera

Alimera

Alimera Sciences is “dedicated to change the paradigm of how we think about and subsequently treat diabetic macular edema (DME),” Mr. Myers said. Iluvien is a fluocinolone (corticosteroid) implant for the treatment of DME. One implant releases 0.2 mcg per day, giving patients up to 3 years’ worth of therapy. Iluvien is “a real advancement…

Read More

Implandata

Implandata - Companies to Watch - 2015

Implandata Ophthalmic Products GmbH (IOP GmbH), located in Hanover/Germany, is destined to transform management of glaucoma patients via a unique solution for early detection of elevated intraocular pressure (IOP), for reliable IOP patient self-measurement, for vastly improved disease monitoring and glaucoma therapy and for more efficient remote patient care. www.implandata.com Participant: Max G. Ostermeier, MBA…

Read More

Implandata’s Hands-On Approach To Tracking IOP

OIS Podcast

Implandata Ophthalmic Products GmbH is putting the task of tracking intraocular pressure into the hands of patients. Company Co-Founder and General Manager Max G. Ostermeier shares the story of EyeMate, an implantable micro sensor capable of measuring absolute intraocular pressure continuously or on demand. Podcast Guest Max G. Ostermeier, MBA Max has extensive experience in…

Read More

Aquesys

Aquesys ASCRS 2015

The XEN Gel Stent is made of a permanent, soft, collagen-derived, gelatin about 6 mm long. Upon implantation, it creates a gentle, diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The ab-interno procedure requires no tissue dissection or suturing. Although the device creates a bleb, there are…

Read More

DigiSight

DigiSight

DigiSight Technologies Inc. is integrating mobile diagnostics into clinical care, with a focus on using technology to administer well-established tests like visual acuity, Amsler grid, and more than 10 others—the results of which all become available through their physician portal. CEO Doug Foster reported that the company has plans in all areas of mobile health,…

Read More